Navigation Links
Modulation in Medical Technology

Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session

... of the OPTIMIZER System's cardiac contractility modulation (CCM) signals when applied for three months. The ... . About Cardiac Contractility modulation (CCM) Therapy Cardiac Contractility modulation is a new treatment for patients with heart ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... in" of an optimal amount of dopamine receptor modulation by simple dose adjustments using a single drug. ... to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic ... of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the ...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

... endovascular catheter-based temperature modulation system, initiated either prior to or after ... to reperfusion with an endovascular temperature modulation system as an adjunct to angioplasty and stent ... Temperature Modulation Patient temperature modulation is a rapidly-advancing field focused ...

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

... 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine ... to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic ... of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the ...

Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs

... 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine ... to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic ... of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the ...

PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium

... through PTC's proprietary GEMS (Gene Expression modulation by Small-Molecules) technology by targeting ... solid tumor types. About GEMS Gene Expression modulation by Small-molecules (GEMS) is PTC's novel ... activities, including the Gene Expression modulation by Small- molecules (GEMS) technology ...

New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression

... therapy (ECT). A critical time for such effective modulation occurs approximately at 30 weeks of treatment. Such modulation could support VNS Therapy's unique mechanism ... Further analysis of the data demonstrates that modulation of the brain is a dynamic process that over time ...

Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology

... medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell ... so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... of PIM kinase may potentiate the activity of m-tor inhibitors by modulation of m-tor inhibitor resistance pathways. These elegant preclinical ... and can induce progression of the cell cycle, inhibition of apoptosis, and modulation of other signal transduction pathways. Therefore, SGI-1776 can induce cell ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... States Patent and Trademark Office granted the patent entitled "Antisense modulation of Apolipoprotein B (apoB) Expression," U.S. Patent No. 7,407,943. The ... differ from that in the U.S. New Patent The patent entitled "Antisense modulation of Apolipoprotein B (apoB) Expression," U.S. Patent No. 7,407,943 is the ...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

... for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby ... shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and ...

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

... class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby ... shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and ...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

... from a similar compound class as Copaxone. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control ... shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and ...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007

... which combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As a dopamine ... may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy in the treatment of bipolar ...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722

... which combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As a dopamine ... may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy in the treatment of bipolar ...

Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

... class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the ... shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and ...

Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia

... a single drug. The ability to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic symptoms without incurring ... may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the treatment of bipolar ...

Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

... class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the ... shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and ...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

... lower doses of anti-CD3 monoclonal antibody, causing partial TCR modulation, are efficacious in this model, and that high doses resulting in full TCR modulation are not required to achieve similar rates of remission. These data, combined with a rigorous Phase 2 clinical development program assessing ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... for our ability to develop an effective treatment for swine flu and other H1N1 flu viruses." L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been ...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

... its antiepileptic effect in humans is not yet clear. In preclinical studies, the mechanism of action for Vimpat(R) has been shown to involve the modulation of sodium channel activity in the nervous system. Sodium channels play a crucial role in regulating the activity of the nervous system to help nerve ...

Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US

... diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead product has completed Phase 2 studies in ...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

... indications. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or ...

VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis

... at VentiRx. "Allergic diseases affect approximately twenty percent of the overall population. Based on strong preclinical data, we expect that modulation of the innate immune response will provide a benefit to people that suffer from these diseases." About VentiRx Pharmaceuticals VentiRx ...

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research

... might provide a safe and effective tool to prevent the formation of polyps and progression into cancer. Tuesday, April 21 modulation of ABCB1-Mediated Multidrug Resistance (MDR) by TransKingdom RNA Interference (tkRNAi) 8 am - noon Hall B-F ...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

... indications. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or ...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

... carcinoma (HCC), and a significant two-fold reduction of tumor mass. These data are being presented at the Keystone Symposium, Therapeutic modulation of RNA Using Oligonucleotides, at Lake Louise, Alberta Canada, on February 12th. Liver cancer is the third cause of cancer death globally, ...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... findings, the first-ever proof of activity of an oral RNAi drug in non-human primates, in a poster at the Keystone Symposia Conference, Therapeutic modulation of RNA Using Oligonucleotides. The conference will be held February 8 - 13 in Lake Louise, Alberta Canada. "Delivery of RNAi into the targeted ...

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology

... of VTX-2337 in patients with late stage cancer. "VTX-2337 is the first selective TLR8 compound to reach the clinic and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications," said Dr. Robert Hershberg, Executive Vice ...

Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia

... diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead product is in Phase 2 studies in dyslipidemic ...

PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients

... control processes and has developed proprietary technologies that it applies in its drug discovery activities, including the Gene Expression modulation by Small-molecules (GEMS) technology, which has been the basis for collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, ...

In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop

... "The opportunity to further evaluate Taligen's TT30 compound in our research activities has been invaluable in our characterization of the effects of modulation of the complement system on animal models of human disease," said Steve Tomlinson, Ph.D. and principal investigator of several studies presented at ...

PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy

... control processes and has developed proprietary technologies that it applies in its drug discovery activities, including the Gene Expression modulation by Small-molecules (GEMS) technology, which has been the basis for collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... research and development activities with its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology. L.E.A.P.S.(TM) is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been ...

Cardium Reports on Second Quarter 2008 Highlights and Financial Results

... . Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or ...

PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124

... knowledge of post- transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression modulation by Small- molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies ...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

... has developed a portfolio of product candidates that address important disease pathways in oncology and inflammatory diseases, including immune modulation by co-stimulatory and checkpoint molecules, inhibition of pro-inflammatory cytokines, and B-cell targeted approaches. In addition to providing an ...

PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity

... knowledge of post- transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression modulation by Small- molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies ...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

... in selected therapeutic areas. KineMed is actively acquiring and advancing drug candidates in indications for which it can demonstrate functional modulation of specific biological pathways that mediate disease: cardiovascular disease, metabolic disease, neurodegenerative diseases and disease of fibrosis. ...

Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System

... that RB006's activity was reversed rapidly and safely by RB007. The article, titled, "A Phase 1b Randomized Study of Antidote-Controlled modulation of Factor IXa Activity in Patients with Stable Coronary Artery Disease", was authored by clinical researchers from the Duke Clinical Research ...
Other Contents
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
(Date:7/11/2014)... in German . ... uses the refraction of X-rays through a specimen instead ... this method are often of much higher quality than ... of Prof. Franz Pfeiffer are particularly interested in developing ... including X-ray phase-contrast imaging. One main goal is to ...
(Date:7/11/2014)... July 10, 2014---A team of researchers from The Chinese ... identified a gene of wild soybean linked to salt ... grow in saline soil. This study published online in ... unveil novel genomic information for crop improvement. , Soybean ... domestication and human selection, cultivated soybeans have less genetic ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2BGI reports a novel gene for salt tolerance found in wild soybean 2
(Date:7/14/2014)... EnergyFirst, manufacturer of all-natural nutritional ... for its great products, thriving customer base, and ... its products as Jim’s Permalean Protein Powders and Jim’s ... EnergyFirst’s lineup of nutritional products. The Permalean brand will ... , Founded in 1999, Permalean’s products were designed to ...
(Date:7/14/2014)... Summer is the best season of the ... beach, swimming and other outdoor adventures. The promotional product experts ... and healthy all summer long. The promo product gurus at ... must-have custom imprinted products everyone must have on hand this ... sunblock. Sunscreen helps protect skin from harmful UV ...
(Date:7/14/2014)... New research and analysis from the national women's ... examines toxic ingredients in tampons, a product used by ... that may be found in the product’s absorptive materials, ... women’s health at risk. , According to WVE’s ... the potential impact of toxic chemical exposure from tampons ...
(Date:7/14/2014)... Cadeon Associates Inc. http://www.cadeon.com ... Money,” today announced that it has joined the ... helps partners resell, deploy, and develop solutions that ... TIBCO Software Inc. is a global leader in ... analytics, providing businesses the ability to capture the ...
(Date:7/13/2014)... 14, 2014 FORT LEE, N.J. – Authors ... modern approach to the science of tooth implants ... This book describes recent advances and techniques in the ... that benefit people who have lost all of their natural ... the first lower subperiosteal implant in 1940. It was ...
Breaking Medicine News(10 mins):Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 3Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4
Other TagsOther Tags